考来烯胺对Graves病的辅助治疗作用

Adjunctive therapy of colestyramine for Graves disease.

目的：评价考来烯胺对Ｇｒａｖｅｓ病的辅助疗效。方法：采用单盲、随机分组对照的设计方法，４０例病人分成３组：①对照组用甲巯咪唑、普萘洛尔４周；②治疗１组用考来烯胺、甲巯咪唑、普萘洛尔４周；③治疗２组用考来烯胺、甲巯咪唑、普萘洛尔２周，后两周停用考来烯胺。结果：第２周末治疗１组较对照组总甲状腺素（ＴＴ４）和游离甲状腺素（ＦＴ４）下降明显，治疗２组与治疗１组相似，第４周末，ＴＴ４、ＦＴ４、总三碘甲状腺原氨酸（ＴＴ３）在治疗１组较对照组下降显著，治疗２组与对照组相近。最终治疗１组６２％甲状腺功能正常，对照组只有８％。

Objective: To evaluate the adjunctive therapeutic effect of cholestyramine for Graves disease. Methods:A single blind, randomized control study was designed, 40 patients were assigned into three groups:①control group: methimazole and propranolol used for 4 weeks;②Cholestyramine treated group 1:methimazole, cholestyramine and propranolol for 4 weeks;③Cholestyramine treated group 2: cholestyramine for 2 weeks, followed by another 2 weeks of methimazole and propranolol. Results: At the end of the second week, TT 4 and FF 4 were significantly lower in group 1 than control group, while there was no difference between group 1 and group 2. At the end of week 4, TT 4,FT 4、TT 3 were significantly lower in both than in control group. By the end of the study, 62% patients in group 1, while only 8% patients in control group were in euthyroid state. Conclusion: Cholestryramine is an effective adjunctive agent for the treatment of Graves disease.